Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
RESEARCH TRIANGLE PARK, N.C., June 06, 2023 -- Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK® in... | June 6, 2023